Sophiris Bio, Inc. (SPHS): Price and Financial Metrics

Sophiris Bio, Inc. (SPHS)

Today's Latest Price: $0.01 USD

0.00 (-25.19%)

Updated Oct 27 9:49pm

Add SPHS to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 384 in Biotech

See all "A" rated Strong Buy stocks

SPHS Stock Price Chart Interactive Chart >

Price chart for SPHS

SPHS Price/Volume Stats

Current price $0.01 52-week high $0.94
Prev. close $0.01 52-week low $0.00
Day low $0.01 Volume 24,900
Day high $0.02 Avg. volume 373,716
50-day MA $0.01 Dividend yield N/A
200-day MA $0.20 Market Cap 359.06K

Sophiris Bio, Inc. (SPHS) Company Bio

Sophiris Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of products for the treatment of urological diseases. The company was formerly known as Protox Therapeutics Inc. and changed its name to Sophiris Bio, Inc. in April 2012. The company was founded in 2002 and is based in La Jolla, California.

SPHS Latest News Stream

Event/Time News Detail
Loading, please wait...

SPHS Latest Social Stream

Loading social stream, please wait...

View Full SPHS Social Stream

Latest SPHS News From Around the Web

Below are the latest news stories about Sophiris Bio Inc that investors may wish to consider to help them evaluate SPHS as an investment opportunity.

Sophiris Bio Announces Nasdaq Delisting

Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage clinical trials for the treatment of patients with urological diseases, today announced that on March 10, 2020, the Nasdaq Office of General Counsel notified the Company that the Nasdaq Hearing Panel (“Panel”) had determined to delist the Company’s shares from The Nasdaq Stock Market LLC (“Nasdaq”), and that trading in the Company’s common shares will be suspended effective at the open of business on March 12, 2020. Nasdaq will thereafter file a Form 25 with the Securities and Exchange Commission (“SEC”) to effect the formal delisting of the Company’s common stock following the expiration of all applicable Nasdaq...

Yahoo | March 10, 2020

SPHS: Single Phase 3 Clinical Trial Planned for Topsalysin in Localized Prostate Cancer…

By David Bautz, PhD NASDAQ:SPHS READ THE FULL SPHS RESEARCH REPORT Business Update Sophiris Bio Inc. (NASDAQ:SPHS) is developing treatments for localized clinically significant prostate cancer and lower urinary tract symptoms of benign prostatic hyperplasia (BPH). The company’s lead candidate, topsalysin (PRX302), is a genetically engineered recombinant protein that is activated through enzymatic

Yahoo | November 18, 2019

Sophiris Bio Reports Third Quarter 2019 Financial Results and Recent Corporate Highlights

SAN DIEGO and VANCOUVER, British Columbia, Nov. 07, 2019 -- Sophiris Bio Inc. (NASDAQ: SPHS), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class,.

Yahoo | November 7, 2019

Sophiris Bio Receives Positive Feedback from FDA Regarding Phase 3 Localized Prostate Cancer Clinical Trial Design

The Phase 3 study design agreed upon with the FDA is consistent with the design previously agreed upon with the European Medicines Agency, as reported in June of this year. The study will enroll approximately 700 patients with a confirmed diagnosis of localized intermediate risk disease, to be equally

ACI Information Group | October 21, 2019

The Daily Biotech Pulse: Enanta Aces Midstage NASH Study, Takeda's Ulcerative Colitis Drug Found Superior To AbbVie's, Decision Day For J&J

The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Sept. 25.) Coherus Biosciences Inc (NASDAQ: CHRS ) The Medicines Company (NASDAQ: MDCO ) Down In The Dumps (Biotech stocks that hit 52-week lows Sept. 25.) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) Advaxis, Inc. (NASDAQ: ADXS ) AnaptysBio Inc (NASDAQ: ANAB ) Aridis Pharmaceuticals Inc (NASDAQ: ARDS ) AzurRx BioPharma Inc (NASDAQ: AZRX ) ( announced lackadaisical efficacy data for pancreatic insufficiency drug) BridgeBio Pharma Inc (NASDAQ: BBIO ) Calithera Biosciences Inc (NASDAQ: CALA ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Catalyst Biosciences Inc (NASDAQ: CBIO ) Cellectis SA (NASDAQ: CLLS ) CytomX Therapeutics Inc (NASDAQ: CT...

Benzinga | September 26, 2019

Read More 'SPHS' Stories Here

SPHS Price Returns

1-mo -37.50%
3-mo -15.25%
6-mo -96.00%
1-year -98.27%
3-year -99.54%
5-year -98.65%
YTD -97.30%
2019 -55.42%
2018 -63.44%
2017 -18.93%
2016 57.30%
2015 229.63%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.6797 seconds.